Measuring Macrophage Activation Markers and Influence on Bile Acid Composition in Patients With Primary Biliary Cholangitis After Treatment With Bezafibrate
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other, Device
Study Type: Observational
SUMMARY
Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients. sCD163, fibrosis markers and bile acid composition are of special interest in PBC. In this study, the investigators will investigate how treatment with bezafibrate influence levels of macrophage activation markers and fibrosis markers as well as bile acid composition in patients offered bezafibrate as add-on therapy to UDCA.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:
• PBC patient offered bezafibrate treatment
Locations
Other Locations
Denmark
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark
RECRUITING
Aarhus N
Department of Medicine, Gastrounit Medical division
RECRUITING
Hvidovre
Contact Information
Primary
Henning Grønbæk, Prof, MD
henngroe@rm.dk
+45 21679281
Backup
Lars Bossen, MD
larsbossen@clin.au.dk
+45 22800676
Time Frame
Start Date: 2020-10-01
Estimated Completion Date: 2026-09
Participants
Target number of participants: 100
Treatments
PBC patients offered bezafibrate treatment
All patients started on bezafibrate treatment are offered inclusion in the study.~First visit is before start of treatment. Afterwards patients will be seen at 4 weeks, 6 months, 1 year, 2 years and 3 years after inclusion.~At all visits blood samples will be taken and liver stiffness will be measured using FibroScan. Further, they will be asked about pruritus.
Related Therapeutic Areas
Sponsors
Leads: University of Aarhus
Collaborators: Hvidovre University Hospital, Aarhus University Hospital